GlobeNewswire Inc.T3·28d ago
FULC Fulcrum Therapeutics, Inc. Common Stock
XNAS
3.71
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
FULC
$3.71
—
Key stats
$3.71
- 52-Week Range
- $2.83 – $15.74
- YTD
- -66.07%
- IV Rank (30D)
- 0.0
- Straddle Price
- $0.85
- P/C Vol Ratio
- 0.05
- Market Cap
- $0.3B
- Open
- $3.71
- Day Range
- $3.69 – $3.71
- Volume
- 96,093
- Prev Close
- $3.70
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.38 |
| Cost of Equity (CAPM) | 12.72% (VRP-adj) |
| WACC | 12.71% |
| Volatility Risk Premium | +239.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -27.4% |
| Book / Price | 120.6% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $3.78 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.71 |
| Bollinger Width / SMA20 | 102.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: BNTC, UNH, UTHR
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$16.56
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $16.56 | 100% | median 3.7× · 3 peers |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $3.78 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 55
- List Date
- 2019-07-18
- CIK
- 0001680581
- Next Earnings
- 2026-11-04 (After-Close)
- EPS Forecast
- ($0.10) (2 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.fulcrumtx.com
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -10.95% | -31.76% | 59.62% | 0.14% | -18.18% | -1.74% | -0.48% |
| Feb | 14.85% | -9.84% | -52.14% | 27.31% | -5.77% | -21.83% | -7.90% |
| Mar | -9.87% | 112.30% | -54.69% | -14.10% | -11.11% | -1.79% | 3.46% |
| Apr | -6.25% | -59.48% | -9.75% | -23.42% | 39.49% | -4.68% | -10.68% |
| May | -21.46% | -27.35% | 0.00% | 7.09% | 56.96% | -5.98% | 1.54% |
| Jun | 19.91% | -29.19% | 14.19% | -24.21% | -1.15% | -42.99% | -10.57% |
| Jul | -28.89% | 19.51% | 17.54% | 47.07% | -1.61% | -4.02% | 8.27% |
| Aug | 306.29% | 31.67% | 49.06% | -5.11% | -5.12% | 4.85% | 63.61% |
| Sep | 5.14% | -1.22% | -22.38% | -55.93% | 43.53% | -4.39% | -5.88% |
| Oct | -22.07% | -31.86% | -11.00% | -12.22% | -6.22% | 0.95%* | -13.74% |
| Nov | -34.12% | 18.10% | 28.00% | 19.94% | 21.29% | -- | 10.64% |
| Dec | 26.36% | 8.66% | 35.27% | 21.13% | 14.59% | -- | 21.20% |
| Total | 60.38% | -62.99% | -25.24% | -46.61% | 159.04% | -62.56% | 3.67% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.70
SMA 50: $3.78
SMA 200: $6.05
Current: $3.71
EMA 12: $3.70
EMA 26: $3.72
MACD: -0.0207 | Signal: 0.0040
BEARISH
ADX (14): 8.05
RANGE
+DI: 16.80
−DI: 14.99
Momentum Oscillators
RSI (14): 47.56
NEUTRAL
Stoch %K: 48.28
Stoch %D: 42.91
Williams %R: -51.72
Volume & Volatility
BB Upper: $3.76
BB Lower: $3.64
NEUTRAL
OBV: 11,505,167
Vol SMA 20: 1,376,481
Vol ROC: -96.46%
ATR: $0.06
True Range: $0.02
HV 20: 14.0%
HV 30: 12.7%
HV 60: 20.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
Here is a structured report with the requested sections:
Executive Summary
Overall assessment: BEARISH (confidence level 7/10)
Key drivers and primary risks:
- Recent negative news headlines surrounding Fulcrum Therapeutics, Inc.
- Bearish MACD signal and histogram indicating potential sell signal
- Moderate volatility compared to market beta (0.95 vs SPY) suggesting some independence
Investment thesis: Short-term bearish sentiment driven by recent negative news headlines may continue, but the stock's moderate volatility and historical trading range suggest potential for a bounce or correction.
Recent news sentiment impact:
- Negative news headlines have led to short-term bearish sentiment, potentially driving prices lower in the near term
Technical Analysis
Trend Direction: Short-term (1-4 weeks) BEARISH, Medium-term (1-3 months) NEUTRAL, Long-term (3-12 months) NEUTRAL
Support/Resistance Levels:
- Lower Bollinger Band: $1.95
- Middle Band: $3.86
- Upper Band: $5.77
- SMA 20: $3.86
- SMA 50: $5.83
- SMA 200: $8.51
Momentum Signals:
- RSI interpretation: Neutral (37.24)
- MACD signal: Bearish (-0.63 / Signal: 0.13 / Histogram: -0.76)
- Bollinger Bands position: Squeeze (price touching lower band)
Volume Analysis: Volume trends and institutional interest signals:
- On-Balance Volume (OBV): 2536740.88
- Volume Rate of Change: 97.33%
- Institutional interest indicated by OBV and volume rate of change
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Recent negative headlines surrounding Fulcrum Therapeutics, Inc.
- Positive earnings results and partnership announcements in the past
- General market commentary and routine announcements
Sentiment Assessment: Aggregate news sentiment (positive/negative/neutral):
- Negative sentiment dominates recent headlines
Catalyst Identification: Upcoming events, earnings, product launches, regulatory changes:
- No imminent catalysts identified
Market Narrative: How news aligns with or contradicts technical signals:
- Recent negative headlines contradict short-term bearish momentum signal from MACD
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market (beta >1.2 = high risk, <0.8 = defensive):
- Beta: 0.95 (moderate risk)
Volatility Regime: Current vs historical volatility levels:
- Stock volatility: 1.00 (moderate)
- Historical volatility: HV20 264.4%, HV30 218.9%, HV60 158.6%
Options Market Signals:
- IV Rank: 48.9% (Medium - shows if volatility is historically high/low)
- Current IV: 310.2%
- Expected Move: $0.47 (21 DTE), 7-DTE: $0.47
- Volume Flow: 71 calls vs 14 puts
- Open Interest: 739 calls vs 4,569 puts
- Put/Call Volume Ratio: 0.20 (Bullish sentiment)
Downside Protection: Support levels and risk management considerations:
- Critical support level at $1.95
- Risk management considerations include stop-loss levels and position sizing
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Fulcrum Therapeutics, Inc. underperforming the market (SPY) in recent months
Institutional Activity: Volume patterns suggesting institutional interest:
- OBV and volume rate of change indicate institutional interest
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- R-squared: 0.12 (moderate correlation)
Relative Valuation: Position within trading range:
- Fulcrum Therapeutics, Inc. is currently trading at the lower end of its historical range
Key Levels & Action Items
Critical Price Levels:
- Support level at $1.95
- Resistance levels at $3.86 and $5.77
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Break above SMA 50 for potential medium-term uptrend
- Break below SMA 20 for potential short-term downtrend
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- No imminent catalysts identified
Risk Management: Stop-loss levels and position sizing considerations:
- Critical support level at $1.95
- Risk management considerations include stop-loss levels and position sizing
Generated
News
All FULC news →
GlobeNewswire Inc.T3·4mo ago
BenzingaT3·4mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·7mo ago
GlobeNewswire Inc.T3·8mo ago
GlobeNewswire Inc.T3·10mo ago
BenzingaT3·10mo ago
GlobeNewswire Inc.T3·10mo ago
GlobeNewswire Inc.T3·11mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
17 of 19 under expected move
Avg Expected Move
24.17%
Avg Actual Move
7.81%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-10 | After-Close | 36.49% | 7.62% | 0.21x | Within |
| 2021-11-04 | After-Close | 14.42% | 5.39% | 0.37x | Within |
| 2022-03-03 | After-Close | 12.82% | 11.37% | 0.89x | Within |
| 2022-05-09 | After-Close | 11.10% | 1.44% | 0.13x | Within |
| 2022-11-08 | After-Close | 4.96% | 7.75% | 1.56x | Exceeded |
| 2023-01-04 | After-Close | 19.32% | 10.39% | 0.54x | Within |
| 2023-03-09 | After-Close | 15.15% | 6.43% | 0.42x | Within |
| 2023-05-15 | After-Close | 32.42% | 4.40% | 0.14x | Within |
| 2023-08-03 | After-Close | 36.36% | 2.60% | 0.07x | Within |
| 2024-02-27 | After-Close | 15.72% | 1.38% | 0.09x | Within |
| 2024-05-13 | After-Close | 12.93% | 7.62% | 0.59x | Within |
| 2024-07-31 | After-Close | 16.16% | 2.91% | 0.18x | Within |
| 2024-11-13 | After-Close | 14.04% | 6.74% | 0.48x | Within |
| 2025-02-25 | After-Close | 45.95% | 10.27% | 0.22x | Within |
| 2025-05-01 | After-Close | 22.26% | 28.31% | 1.27x | Exceeded |
| 2025-07-29 | Pre-Market | 55.38% | 2.82% | 0.05x | Within |
| 2025-10-29 | After-Close | 34.99% | 8.12% | 0.23x | Within |
| 2026-02-24 | Pre-Market | 34.44% | 21.21% | 0.62x | Within |
| 2026-04-27 | Pre-Market | 24.23% | 1.53% | 0.06x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
FULC Options Activity & IV Rank
FULC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 41.9%
7-DTE IV: —
Expected Move: $0.85
7-DTE Move: $0.85
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 20
Put Volume: 1
P/C Volume: 0.05
BULLISH
Call OI: 20
Put OI: 1
P/C OI: 0.05
Total OI: 21
ATM Options Pricing
ATM Call: $0.38
ATM Put: $0.47
Call %: 10.1%
Put %: 12.8%
Chain Summary
Chain Volume: 1,651
Chain OI: 18,178
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 87th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
87%
vs own history
GEX tilt
+0.94
OI-weighted, today
Vanna tilt
+0.93
δ-sensitivity to IV
Charm tilt
-0.94
δ-decay vs time
Vanna tilt +0.93: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.94: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 89.3% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)0.0LowOct 22
Straddle Price (30 DTE)$0.85Oct 22
Beta Analysis
Risk Metrics
Beta: 0.5651
Alpha: -48.73%
Correlation: 0.0768
R-Squared: 0.6%
Stock Volatility: 93.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own FULC
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $9.9M | #1597 of 6285 | +109.2% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $6.0M | #1347 of 3138 | +12016.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $5.4M | #2004 of 3716 | +316.8% | 13F | |
| Point72 Hedge fund Steve Cohen | $2.4M | #1214 of 1945 | -68.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $2K | #4437 of 4729 | -52.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
FULC Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 69,607,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$3.40M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SILVERARC CAPITAL MANAGEMENT, LLC | $1.43M | 42.18% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $900.36K | 26.48% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $443.96K | 13.06% | 2026-06-30 |
| 4 | Susquehanna International Group, LLP Custodian | $263.52K | 7.75% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $161.77K | 4.76% | 2026-06-30 |
| 6 | Citadel Advisors LLC Custodian | $124.44K | 3.66% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $53.80K | 1.58% | 2026-06-30 |
| 8 | LMR Partners LLP | $18.30K | 0.54% | 2026-06-30 |
6 filers$2.08M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $743.71K | 35.81% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $641.96K | 30.91% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $336.35K | 16.20% | 2026-06-30 |
| 4 | GROUP ONE TRADING LLC Custodian | $153.72K | 7.40% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $113.09K | 5.45% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $87.84K | 4.23% | 2026-06-30 |
FULC Insider Trading (Form 4)
Latest: 2026-07-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-20 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy (P) | +335,232 | $3.55 | $1.19M | EDGAR |
| 2026-07-15 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | Buy (P) | +499,892 | $3.57 | $1.78M | EDGAR |
| 2026-07-02 | Kate Haviland | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | James A Geraghty | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | Colin Hill | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | Alan Ezekowitz | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | Robert J Gould | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | Rachel K. King | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | Katina Dorton | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-07-02 | Sonja Banks | Director | Grant (A) | +32,000 opt | — | EDGAR | |
| 2026-05-01 | Joshua Lehrer-Graiwer | Director | Grant (A) | +64,000 opt | — | EDGAR | |
| 2026-02-04 | Robert J Gould | Director | Sell (S) | −15,000 | $10.72 | -$160.9K | EDGAR |
| 2026-02-04 | Curtis Gale Oltmans | Chief Legal Officer | Grant (A) | +170,000 opt | — | EDGAR | |
| 2026-02-04 | Alex Sapir | See Remarks | Grant (A) | +650,000 opt | — | EDGAR | |
| 2026-02-04 | Greg Tourangeau | Principal Accounting Officer | Grant (A) | +57,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
FULC Insider Holdings
7 insiders · @ $3.71
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Rajeev M. Shah | 10%+ Owner | 8,852,079 | $32.84M | -$233.41M | 2 | 2025-12-10 |
| 2 | TANG CAPITAL MANAGEMENT LLC | 10%+ Owner | 7,030,000 | $26.08M | $2.97M | 2 | 2026-07-20 |
| 3 | Robert J Gould | Director | 469,864 | $1.74M | -$5.10M | 29 | 2026-07-02 |
| 4 | Alex Sapir | See Remarks | 193,360 | $717.4K | $492.0K | 4 | 2026-02-04 |
| 5 | James A Geraghty | Director | 90,714 | $336.5K | $91.6K | 9 | 2026-07-02 |
| 6 | Greg Tourangeau | Principal Accounting Officer | 14,062 | $52.2K | -$62.3K | 10 | 2026-02-04 |
| 7 | Curtis Gale Oltmans | Chief Legal Officer | 10,252 | $38.0K | -$34.8K | 10 | 2026-02-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
FULC Board & Officers
As of SEC filings through Jul 20, 2026Directors 10
- Alan Ezekowitz · since Jul 17, 2019
- James A Geraghty · since Jul 17, 2019
- Kate Haviland · since Jul 17, 2019
- Robert J Gould · since Jul 17, 2019
- Katina Dorton · since Jan 2, 2020
- Sonja Banks · since Dec 8, 2021
- Alex Sapir · since Jul 1, 2023
- Colin Hill · since Jun 17, 2024
- Rachel K. King · since Nov 12, 2024
- Joshua Lehrer-Graiwer · since Apr 23, 2026
Officers 2
- Alex Sapir · President & Chief Executive Officer · since Jul 1, 2023
- Curtis Gale Oltmans · Chief Legal Officer · listed since Aug 2022
10% owners 6
- Kevin Tang · since Jul 13, 2026
- Peter Kolchinsky · listed since Sep 2024
- RA Capital Healthcare Fund LP (entity) · listed since Sep 2024
- Ra Capital Management, L.p. (entity) · listed since Sep 2024
- Rajeev M. Shah · listed since Sep 2024
- Tang Capital Management LLC (entity) · since Jul 13, 2026
Changes in the last 10 years (92)
| Jul 13, 2026 | Tang Capital Management LLC became a 10% owner |
| Jul 13, 2026 | Kevin Tang became a 10% owner |
| Jun 10, 2026 | The company announced the departure of Greg Tourangeau as Principal Accounting Officer in an SEC filing |
| Apr 23, 2026 | The company announced the departure of Alan A Musso as Chief Financial Officer in an SEC filing |
| Apr 23, 2026 | Joshua Lehrer-Graiwer became a director |
| Nov 12, 2024 | The company announced the departure of James J. Collins from the board in an SEC filing |
| Nov 12, 2024 | Rachel K. King became a director |
| Sep 23, 2024 | Rajeev M. Shah first listed as a 10% owner in an SEC filing |
| Sep 23, 2024 | Ra Capital Management, L.p. first listed as a 10% owner in an SEC filing |
| Sep 23, 2024 | RA Capital Healthcare Fund LP first listed as a 10% owner in an SEC filing |
| Sep 23, 2024 | Peter Kolchinsky first listed as a 10% owner in an SEC filing |
| Aug 23, 2024 | Rajeev M. Shah reported in an SEC filing no longer being a 10% owner |
| Aug 23, 2024 | Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner |
| Aug 23, 2024 | RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner |
| Aug 23, 2024 | Peter Kolchinsky reported in an SEC filing no longer being a 10% owner |
| Jun 18, 2024 | Robert J Gould no longer listed as Interim President & CEO in SEC filings |
| Jun 17, 2024 | Colin Hill became a director |
| May 9, 2024 | Greg Tourangeau listed as Principal Accounting Officer (previously Vice President, Finance) in SEC filings |
| Mar 18, 2024 | Patrick Taylor Horn became Chief Medical Officer |
| Jan 30, 2024 | Greg Tourangeau listed as Vice President, Finance (previously Controller) in SEC filings |
| Aug 7, 2023 | Alan A Musso became Chief Financial Officer |
| Jul 1, 2023 | Alex Sapir became a director |
| Jul 1, 2023 | Alex Sapir became President & Chief Executive Officer |
| Mar 31, 2023 | The company announced the departure of Esther Rajavelu as Chief Financial Officer in an SEC filing |
| Jan 13, 2023 | Robert J Gould first listed as Interim President & CEO in an SEC filing |
| Dec 15, 2022 | Trv Gp III, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2022 | Third Rock Ventures III, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2022 | Third Rock Ventures GP III, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 15, 2022 | Robert I Tepper reported in an SEC filing no longer being a 10% owner |
| Nov 7, 2022 | Santiago Arroyo became Chief Medical Officer |
| Oct 14, 2022 | The company announced the departure of Judith Dunn as President, Research & Development in an SEC filing |
| Aug 16, 2022 | Rajeev M. Shah became a 10% owner |
| Aug 16, 2022 | Ra Capital Management, L.p. became a 10% owner |
| Aug 16, 2022 | RA Capital Healthcare Fund LP became a 10% owner |
| Aug 16, 2022 | Peter Kolchinsky became a 10% owner |
| Aug 11, 2022 | Curtis Gale Oltmans listed as Chief Legal Officer (previously SVP, General Counsel) in SEC filings |
| Aug 9, 2022 | Melvin H. Hayes III became Chief Operating Officer |
| Jul 8, 2022 | The company announced the departure of Christopher Morabito as Chief Medical Officer in an SEC filing |
| Apr 5, 2022 | Robert J Gould no longer listed as President & Chief Executive Officer in SEC filings |
| Mar 11, 2022 | Greg Tourangeau became Controller |
| Jan 5, 2022 | The company announced the departure of Mark J Levin from the board in an SEC filing |
| Jan 3, 2022 | Esther Rajavelu became Chief Financial Officer |
| Dec 8, 2021 | Sonja Banks became a director |
| Aug 12, 2021 | Bryan Stuart listed as President & Chief Executive Officer (previously Chief Operating Officer) in SEC filings |
| May 10, 2021 | Christopher Morabito became Chief Medical Officer |
| Apr 2, 2021 | Bryan Stuart first listed as a director in an SEC filing |
| Mar 23, 2021 | Judith Dunn became President, Research & Development |
| Feb 6, 2021 | Christopher Moxham became Chief Scientific Officer |
| Nov 30, 2020 | Curtis Gale Oltmans became SVP, General Counsel |
| Jan 27, 2020 | Robert J Gould no longer listed as a 10% owner in SEC filings |
| Jan 2, 2020 | Katina Dorton became a director |
| Jul 24, 2019 | Glaxosmithkline Plc reported in an SEC filing no longer being a 10% owner |
| Jul 23, 2019 | Sanofi reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | William J Maris reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | Section 32 GP 2, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | Section 32 Fund 2, LP reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | Eli Casdin reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | Casdin Partners Master Fund, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | Casdin Partners GP, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | Casdin Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Jul 22, 2019 | 6 Dimensions Capital, L.P. reported in an SEC filing no longer being a 10% owner |
| Jul 17, 2019 | William J Maris became a 10% owner |
| Jul 17, 2019 | Trv Gp IV, LLC became a 10% owner |
| Jul 17, 2019 | Trv Gp III, LLC became a 10% owner |
| Jul 17, 2019 | Third Rock Ventures IV, L.P. became a 10% owner |
| Jul 17, 2019 | Third Rock Ventures III, L.P. became a 10% owner |
| Jul 17, 2019 | Third Rock Ventures GP IV, L.P. became a 10% owner |
| Jul 17, 2019 | Third Rock Ventures GP III, L.P. became a 10% owner |
| Jul 17, 2019 | Section 32 GP 2, LLC became a 10% owner |
| Jul 17, 2019 | Section 32 Fund 2, LP became a 10% owner |
| Jul 17, 2019 | Sanofi became a 10% owner |
| Jul 17, 2019 | Robert J Gould became a director |
| Jul 17, 2019 | Robert J Gould became a 10% owner |
| Jul 17, 2019 | Robert J Gould became President & Chief Executive Officer |
| Jul 17, 2019 | Robert I Tepper became a 10% owner |
| Jul 17, 2019 | Peter G. Thomson became VP Finance & Accounting |
| Jul 17, 2019 | Owen B. Wallace became Chief Scientific Officer |
| Jul 17, 2019 | Mark J Levin became a director |
| Jul 17, 2019 | Mark J Levin became a 10% owner |
| Jul 17, 2019 | Kevin P Starr became a 10% owner |
| Jul 17, 2019 | Kate Haviland became a director |
| Jul 17, 2019 | James J. Collins became a director |
| Jul 17, 2019 | James A Geraghty became a director |
| Jul 17, 2019 | Glaxosmithkline Plc became a 10% owner |
| Jul 17, 2019 | Eli Casdin became a 10% owner |
| Jul 17, 2019 | Diego Cadavid became SVP Clinical Development |
| Jul 17, 2019 | Casdin Partners Master Fund, L.P. became a 10% owner |
| Jul 17, 2019 | Casdin Partners GP, LLC became a 10% owner |
| Jul 17, 2019 | Casdin Capital, LLC became a 10% owner |
| Jul 17, 2019 | Bryan Stuart became Chief Operating Officer |
| Jul 17, 2019 | Alan Ezekowitz became a director |
| Jul 17, 2019 | 6 Dimensions Capital, L.P. became a 10% owner |
Not reported recently (13)
- Patrick Taylor Horn · Last reported as Chief Medical Officer in an SEC filing dated Mar 20, 2024
- Melvin H. Hayes III · Last reported as Chief Operating Officer in an SEC filing dated Apr 28, 2023
- Santiago Arroyo · Last reported as Chief Medical Officer in an SEC filing dated Nov 9, 2022
- Bryan Stuart · Last reported as a director in an SEC filing dated Jan 21, 2022
- Peter G. Thomson · Last reported as VP Finance & Accounting in an SEC filing dated Jan 21, 2022
- Mark J Levin · Last reported as a 10% owner in an SEC filing dated Nov 12, 2021
- Kevin P Starr · Last reported as a 10% owner in an SEC filing dated Nov 12, 2021
- Christopher Moxham · Last reported as Chief Scientific Officer in an SEC filing dated Aug 12, 2021
- Owen B. Wallace · Last reported as Chief Scientific Officer in an SEC filing dated Sep 14, 2020
- Diego Cadavid · Last reported as SVP Clinical Development in an SEC filing dated Jul 2, 2020
- Trv Gp IV, LLC · Last reported as a 10% owner in an SEC filing dated Jul 22, 2019
- Third Rock Ventures GP IV, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 22, 2019
- Third Rock Ventures IV, L.P. · Last reported as a 10% owner in an SEC filing dated Jul 22, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
FULC Proposed Insider Sales (Form 144)
Latest: 2026-06-26
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | ALAN EZEKOWITZ | Director | 18,000 | $65.0K | 2026-06-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-15 | CURTIS G OLTMANS | Officer | 3,452 | $44.9K | 2025-12-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2025-12-08 | RA Capital Healthcare Fund LP | 10% Stockholder | 4,175,139 | $54.24M | 2025-12-08 | BTIG, LLC | — | EDGAR |
| 2025-11-19 | ROBERT J GOULD | Director | 45,000 | $437.9K | 2025-11-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-03-08 | Greg Tourangeau | Officer | 4,884 | $57.2K | 2024-03-08 | Merrill Lynch, Pierce, Fenner & … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
36 ETFs hold FULC
25 shown · $31.95M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $7.7M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $6.4M | $75.1B | 2026-10-20 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.7M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.3M | $13.7B | 2026-10-20 |
| 5 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.02% | $2.1M | $11.0B | 2026-10-20 |
| 6 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.03% | $1.9M | $6.6B | 2026-10-20 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.6M | — | 2026-05-31 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.5M | — | 2026-09-30 |
| 9 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $786,341 | — | 2026-10-20 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.06% | $763,430 | $1.2B | 2026-10-20 |
| 11 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.01% | $655,590 | — | 2026-10-20 |
| 12 | PINK Simplify Health Care ETF | Nport | 0.16% | $562,886 | — | 2026-06-30 |
| 13 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $526,403 | — | 2026-09-30 |
| 14 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $525,536 | $3.1B | 2026-10-20 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $504,510 | — | 2026-10-20 |
| 16 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $411,871 | $97.4B | 2026-10-20 |
| 17 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.01% | $293,592 | — | 2026-07-31 |
| 18 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.02% | $232,268 | — | 2026-09-30 |
| 19 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $210,209 | — | 2026-05-31 |
| 20 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $121,068 | — | 2026-10-21 |
| 21 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $87,580 | $20.6B | 2026-10-20 |
| 22 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Nport | 0.02% | $50,703 | — | 2026-05-31 |
| 23 | AVUS Avantis U.S. Equity ETF | Avantis | 0.00% | $40,909 | $14.8B | 2026-10-20 |
| 24 | DFUS Dimensional US Equity Market ETF | Dimensional | 0.00% | $37,379 | $21.4B | 2026-10-20 |
| 25 | IBBQ Invesco Nasdaq Biotechnology ETF | Nport | 0.04% | $24,227 | — | 2026-05-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.21
TTM Revenue
—
TTM Net Income
$-85.00M
TTM Op. Cash Flow
$-65.78M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-26.18M | $-0.34 | $-16.04M |
| Q1 '26 | 2026-03-31 | — | $-18.89M | $-0.25 | $-18.75M |
| Q4 '25 | 2025-12-31 | — | $-20.33M | $-0.31 | $-16.80M |
| Q3 '25 | 2025-09-30 | — | $-19.59M | $-0.31 | $-14.19M |
| Q2 '25 | 2025-06-30 | — | $-17.30M | $-0.28 | $-13.82M |
| Q1 '25 | 2025-03-31 | — | $-17.66M | $-0.28 | $-15.26M |
| Q4 '24 | 2024-12-31 | $0.00 | $-16.57M | $-0.27 | $-16.76M |
| Q3 '24 | 2024-09-30 | — | $-21.70M | $-0.35 | $-19.07M |
| Q2 '24 | 2024-06-30 | $80.00M | $55.41M | $0.87 | $58.90M |
| Q1 '24 | 2024-03-31 | — | $-26.87M | $-0.43 | $-25.28M |
| Q4 '23 | 2023-12-31 | $871.00K | $-24.76M | $-0.40 | $-23.16M |
| Q3 '23 | 2023-09-30 | $759.00K | $-24.02M | $-0.39 | $-22.91M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.83
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-27.4%
ROA
-26.2%
Div Yield
0.00%
FCF Yield
-25.44%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$258.59M
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.11M
SI % of Float
11.14%
Days to Cover
4.48
Short Vol Ratio
62.9%
Free Float
63.83M
Float %
83.7%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-19